As a core enterprise in the continuous glucose monitor (CGM) sector, Abbott officially announced a major strategic partnership with French health technology brand Withings at the 2026 Consumer Electronics Show (CES 2026) in the United States. The two parties will achieve in-depth integration between Abbott's Lingo CGM and the Withings App, marking that existing Withings users can synchronize and consolidate blood glucose monitoring data from the Lingo CGM with data collected by Withings devices such as smartwatches, body scales, and sleep monitoring mats into a single application, realizing centralized management of health data.
Initially designed for groups with specific health needs, CGMs have gradually become a daily health monitoring tool for general consumers. This development trend is highly aligned with Withings' brand philosophy. Since its establishment 17 years ago, the brand has been committed to developing health management products with high-quality user experience, assisting users in long-term tracking of personal health data and progressively establishing healthy living habits.
In 2026, Withings officially identified "Longevity" as its core development axis for the future. It plans to further promote the public to proactively track health conditions and develop healthy lifestyles through multiple approaches such as continuous optimization of its own product portfolio and deepening cross-brand strategic cooperation, thereby effectively practicing the core tenet of health management: "Prevention is better than cure."
The new features launched through this cooperation will be officially available in early Q1 2026. Users need to complete the pairing settings between the Withings App and the health platform of the corresponding operating system in advance (compatible with Apple HealthKit for iOS systems and Personal Health Connect for Android systems).
Share:
World’s First Science-Backed Longevity Station
Official Statement by Withings HK Limited